SAN DIEGO, Feb. 21 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN)
will host a conference call on Thursday, February 23, 2006 at 4:30 p.m.
Eastern (1:30 p.m. Pacific) to discuss preliminary 2005 fourth quarter and
year-end financial results. The financial results press release will be
issued at close of market on February 23rd. Interested investors and others
may participate in the conference call by dialing 877-407-9210 for US/Canada
participants, and 201-689-8049 for international participants.
Audio of management's presentation will also be available via live webcast
on the investor relations section of Nanogen's corporate website at
www.nanogen.com, and will be archived for 90 days. A digital recording of the
call will also be available for 48 hours, beginning two hours after the
completion of the conference call on February 23, and can be accessed via
telephone at 877-660-6853 for US/Canada callers, and 201-612-7415 for
international callers. The account number, 286, along with the conference
ID, 194025, will be required to listen to the playback.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose, and
ultimately help treat disease. The company's products include real-time PCR
reagents, the NanoChip(R) electronic microarray platform and a line of rapid,
point-of-care diagnostic tests. Nanogen's ten years of pioneering research
involving nanotechnology holds the promise of miniaturization and continues to
be supported for its potential for diagnostic and biowarfare applications.
For additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.